Franck E. Nicolini
About
Franck E. Nicolini is a scholar working on Hematology, Genetics and Rheumatology.
According to data from OpenAlex, Franck E. Nicolini has authored 56 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Hematology, 48 papers in Genetics and 28 papers in Rheumatology. Recurrent topics in Franck E. Nicolini's work include Chronic Myeloid Leukemia Treatments (54 papers), Chronic Lymphocytic Leukemia Research (44 papers) and Eosinophilic Disorders and Syndromes (28 papers). Franck E. Nicolini is often cited by papers focused on Chronic Myeloid Leukemia Treatments (54 papers), Chronic Lymphocytic Leukemia Research (44 papers) and Eosinophilic Disorders and Syndromes (28 papers). Franck E. Nicolini collaborates with scholars based in France, Canada and United States. Franck E. Nicolini's co-authors include Delphine Réa, François‐Xavier Mahon, Laurence Legros, François Guilhot, Gabriel Étienne, Joëlle Guilhot, Bruno Varet, Aude Charbonnier, Philippe Rousselot and Françoise Huguet and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
In The Last Decade
Franck E. Nicolini
56 papers receiving 2.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Franck E. Nicolini France | 19 | 2.7k | 2.1k | 1.2k | 501 | 400 | 56 | 3.0k | ||
| Philipp D. le Coutre Germany | 23 | 2.3k 0.8× | 1.9k 0.9× | 1.2k 1.0× | 449 0.9× | 194 0.5× | 72 | 2.5k | ||
| Concepción Boqué Spain | 9 | 2.0k 0.7× | 1.6k 0.8× | 1.0k 0.8× | 345 0.7× | 227 0.6× | 23 | 2.3k | ||
| M. Brigid Bradley‐Garelik United States | 15 | 2.2k 0.8× | 1.9k 0.9× | 1.2k 1.0× | 351 0.7× | 190 0.5× | 28 | 2.5k | ||
| Beatriz Moiraghi Argentina | 13 | 1.8k 0.7× | 1.5k 0.7× | 1.0k 0.8× | 309 0.6× | 222 0.6× | 42 | 2.1k | ||
| Laurence Legros France | 30 | 3.6k 1.4× | 2.7k 1.3× | 1.5k 1.2× | 681 1.4× | 723 1.8× | 126 | 4.1k | ||
| Athena Countouriotis United States | 14 | 1.6k 0.6× | 1.4k 0.7× | 943 0.8× | 323 0.6× | 178 0.4× | 21 | 1.9k | ||
| Ron Paquette United States | 12 | 1.8k 0.7× | 1.2k 0.5× | 625 0.5× | 390 0.8× | 540 1.4× | 23 | 2.2k | ||
| Franck E. Nicolini France | 19 | 1.5k 0.6× | 1.2k 0.6× | 697 0.6× | 253 0.5× | 195 0.5× | 64 | 1.7k | ||
| Marilina Amabile Italy | 28 | 2.5k 0.9× | 1.6k 0.8× | 1.1k 0.9× | 423 0.8× | 522 1.3× | 80 | 2.9k | ||
| Anna Turkina Russia | 17 | 1.2k 0.4× | 1.0k 0.5× | 544 0.4× | 296 0.6× | 234 0.6× | 134 | 1.5k |
Countries citing papers authored by Franck E. Nicolini
Since
Specialization
Citations
This map shows the geographic impact of Franck E. Nicolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck E. Nicolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck E. Nicolini more than expected).
Fields of papers citing papers by Franck E. Nicolini
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Franck E. Nicolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck E. Nicolini. The network helps show where Franck E. Nicolini may publish in the future.
Co-authorship network of co-authors of Franck E. Nicolini
This figure shows the co-authorship network connecting the top 25 collaborators of Franck E. Nicolini. A scholar is included among the top collaborators of Franck E. Nicolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck E. Nicolini. Franck E. Nicolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Étienne, Gabriel, Stéphanie Dulucq, Françoise Huguet, et al.. (2019). Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Medicine. 8(11). 5173–5182.
2.
Dumas, Pierre‐Yves, Emilie Bérard, Stéphanie Dulucq, et al.. (2019). Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission. Cancer Medicine. 8(11). 4976–4985.
3.
Réa, Delphine, Shanti Amé, Aude Charbonnier, et al.. (2016). Recommandations 2015 du France Intergroupe des Leucémies Myéloïdes Chroniques pour la gestion du risque d’événements cardiovasculaires sous nilotinib au cours de la leucémie myéloïde chronique. Bulletin du Cancer. 103(2). 180–189.
4.
Berger, Marc, Bruno Pereira, Charlotte Oris, et al.. (2015). Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort. Blood. 126(23). 137–137.
5.
Heiblig, Maël, Mohamed Elhamri, Isabelle Tigaud, et al.. (2015). TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases. 8(1). 2016009–2016009.
6.
Huet, Sarah, Pascale Cony‐Makhoul, Maël Heiblig, et al.. (2014). Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended. PLoS ONE. 9(9). e106250–e106250.
7.
Réa, Delphine, Michaela Schwarz, Franck E. Nicolini, et al.. (2013). Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 27(6). 1316–1321.
8.
Rousselot, Philippe, Pascale Cony‐Makhoul, Franck E. Nicolini, et al.. (2012). Long‐term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study. American Journal of Hematology. 88(1). 1–4.
9.
Nicolini, Franck E., Tamás Masszi, Zhixiang Shen, et al.. (2011). Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leukemia & lymphoma. 53(5). 907–914.
10.
Rousselot, Philippe, Pascale Cony Makhoul, Delphine Réa, et al.. (2011). Fluctuating Values of Molecular Residual Disease (MRD) without Molecular Progression After Imatinib Discontinuation in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Have Maintained Complete Molecular Response: Implications for Re-Treatment Criteria and Role of Prior Interferon Therapy. A Pilot Study of the French CML Group (FILMC),. Blood. 118(21). 3781–3781.
11.
Soverini, Simona, Andreas Hochhaus, Franck E. Nicolini, et al.. (2011). BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 118(5). 1208–1215.
12.
Nicolini, Franck E., Sandrine Hayette, Laurence Legros, et al.. (2010). Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. Leukemia Research. 35(1). 80–86.
13.
Jiang, Xiaoyan, Donna L. Forrest, Franck E. Nicolini, et al.. (2010). Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood. 116(12). 2112–2121.
14.
Nicolini, Franck E., Jean‐Claude Chomel, Lydia Roy, et al.. (2010). The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge. Clinical Lymphoma Myeloma & Leukemia. 10(5). 394–399.
15.
Mahon, François‐Xavier, Delphine Réa, Joëlle Guilhot, et al.. (2010). Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. The Lancet Oncology. 11(11). 1029–1035.
16.
Nicolas‐Virelizier, Emmanuelle, Matthias Jacquet‐Lagrèze, Delphine Réa, et al.. (2009). Combined Chemotherapy (daunorubicin + cytarabine) and Dasatinib as Salvage Therapy of Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis, a Pilot Study.. Blood. 114(22). 2195–2195.
17.
Nicolini, Franck E., Emmanuel Bachy, Sélim Corm, et al.. (2006). Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.. Blood. 108(11). 2190–2190.
18.
Hayette, Sandrine, et al.. (2005). Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. Leukemia Research. 29(9). 1073–1077.
19.
Chabane, Kaddour, Franck E. Nicolini, Jean‐Michel Cayuela, et al.. (2005). The K247R Substitution in ABL Tyrosine Kinase Domain Is Not a Mutation Leading to Imatinib Resistance but a Polymorphism Rarely Present in CML Patients and in Normal Subjects.. Blood. 106(11). 4831–4831.
20.
Bories, Dominique, Agnès Devergie, M Gardembas-Pain, et al.. (2003). Stratégies thérapeutiques et recommandations pour la prise en charge des patients atteints de leucémie myéloïde chronique. Hématologie. 9(6). 497–512.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Philipp D. le Coutre Breakdown of academic impact, for papers by Concepción Boqué Breakdown of academic impact, for papers by M. Brigid Bradley‐Garelik Breakdown of academic impact, for papers by Beatriz Moiraghi Breakdown of academic impact, for papers by Laurence Legros Breakdown of academic impact, for papers by Athena Countouriotis Breakdown of academic impact, for papers by Ron Paquette Breakdown of academic impact, for papers by Franck E. Nicolini Breakdown of academic impact, for papers by Marilina Amabile Breakdown of academic impact, for papers by Anna Turkina